FDC Ltd

FDC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

FDC Ltd

₹ 423 0.45%
02 May - close price
fdcindia.com BSE: 531599 NSE: FDC
About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

Key Points

Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]

Website BSE NSE
  • Market Cap ₹ 6,885 Cr.
  • Current Price ₹ 423
  • High / Low ₹ 659 / 359
  • Stock P/E 25.2
  • Book Value ₹ 140
  • Dividend Yield 1.18 %
  • ROCE 18.5 %
  • ROE 14.3 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 12.0% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE Allcap BSE SmallCap BSE 400 MidSmallCap Index Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
341 337 493 446 407 431 530 480 452 454 624 505 459
298 319 413 395 360 377 410 401 370 396 482 433 413
Operating Profit 43 17 80 51 47 54 120 79 82 58 142 72 46
OPM % 13% 5% 16% 11% 11% 12% 23% 16% 18% 13% 23% 14% 10%
13 12 19 29 19 10 30 27 25 21 28 35 19
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 10 10 10 10 10 10 10 11 14 13
Profit before tax 47 19 89 69 54 53 139 95 96 67 158 92 50
Tax % 32% 24% 18% 25% 27% 30% 22% 24% 19% 28% 27% 20% 28%
32 14 73 51 39 37 109 72 78 48 115 74 36
EPS in Rs 1.87 0.85 4.40 3.09 2.38 2.24 6.54 4.42 4.81 2.96 7.06 4.54 2.24
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
764 836 877 986 1,008 1,061 1,074 1,328 1,323 1,516 1,777 1,916 2,042
581 630 680 759 766 835 854 1,033 999 1,269 1,522 1,578 1,724
Operating Profit 183 206 197 227 242 225 220 295 324 247 255 338 318
OPM % 24% 25% 22% 23% 24% 21% 20% 22% 25% 16% 14% 18% 16%
48 38 44 40 44 45 51 71 97 79 54 103 102
Interest 2 3 2 1 1 1 1 3 3 3 4 4 4
Depreciation 28 25 38 34 35 35 33 37 38 37 39 40 48
Profit before tax 201 217 201 232 250 234 236 325 380 285 266 398 367
Tax % 21% 38% 27% 27% 25% 28% 27% 24% 23% 23% 24% 23%
158 134 146 169 187 168 172 247 294 220 201 307 274
EPS in Rs 8.67 7.56 8.20 9.50 10.52 9.65 9.84 14.43 17.45 13.01 12.11 18.87 16.80
Dividend Payout % 26% 30% 28% 24% 21% 0% 0% 6% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 9%
5 Years: 12%
3 Years: 13%
TTM: 8%
Compounded Profit Growth
10 Years: 9%
5 Years: 11%
3 Years: 2%
TTM: -8%
Stock Price CAGR
10 Years: 11%
5 Years: 12%
3 Years: 17%
1 Year: -6%
Return on Equity
10 Years: 14%
5 Years: 14%
3 Years: 12%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 18 18 18 18 18 18 18 17 17 17 17 16 16
Reserves 762 823 912 1,059 1,246 1,245 1,416 1,525 1,705 1,932 1,964 2,081 2,270
1 1 1 1 1 1 1 15 14 31 28 20 20
177 209 209 181 195 224 192 249 207 274 327 341 358
Total Liabilities 959 1,051 1,140 1,259 1,459 1,488 1,625 1,806 1,943 2,254 2,335 2,459 2,665
277 272 381 671 674 670 678 670 685 701 695 676 800
CWIP 7 18 29 20 6 13 12 24 19 104 198 261 143
Investments 422 423 496 325 491 472 585 665 790 886 806 850 1,073
252 338 234 243 287 333 349 447 448 563 637 672 649
Total Assets 959 1,051 1,140 1,259 1,459 1,488 1,625 1,806 1,943 2,254 2,335 2,459 2,665

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
149 149 127 171 153 148 104 239 210 162 165 221
-105 -55 -89 -73 -144 20 -109 -85 -84 -147 4 -18
-62 -75 -47 -97 0 -169 -0 -142 -126 -10 -180 -202
Net Cash Flow -18 19 -10 1 10 -2 -6 12 -1 5 -11 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 21 27 25 24 28 26 28 34 30 19 25 22
Inventory Days 117 115 133 134 148 166 183 180 189 210 180 217
Days Payable 72 91 95 85 81 101 82 101 68 94 100 104
Cash Conversion Cycle 67 51 64 73 95 92 130 113 151 135 106 134
Working Capital Days 25 3 12 22 24 28 44 42 49 46 50 54
ROCE % 24% 25% 21% 22% 21% 19% 18% 22% 22% 15% 13% 18%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.50% 69.49% 69.49% 69.49% 69.49% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66%
4.34% 3.99% 3.77% 3.80% 2.06% 2.42% 2.43% 2.65% 2.51% 2.62% 2.67% 2.56%
6.07% 6.77% 7.76% 8.27% 9.13% 8.12% 7.76% 6.94% 6.72% 6.02% 6.08% 6.37%
20.09% 19.75% 18.98% 18.44% 19.32% 19.80% 20.15% 20.76% 21.11% 21.71% 21.60% 21.42%
No. of Shareholders 65,31863,17259,87157,01256,71756,92855,34152,37750,63455,40055,22853,880

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls